Reproductive Health

Evaluating the safety profile of mifepristone

April 22, 2024 - Mifepristone, commonly known as the abortion pill, is a medication used primarily for medically induced abortions as well as the management of Cushing's syndrome and uterine leiomyomas. Since its approval in 2000, mifepristone has been the subject of extensive research and scrutiny, although it has a favorable safety profile.  The safety evaluation of mifepristone has gained...

Read More


More Articles

Walgreens Specialty Pharmacy leads RVVC care with VIVJOA exclusivity

by Alivia Kaylor

In a move set to revolutionize treatment options for post-menopausal women and those not of reproductive potential, Walgreens specialty pharmacy patients now have exclusive access to VIVJOA, an...

SCOTUS to issue a decision on mifepristone in the coming months

by Veronica Salib

The Supreme Court of the United States (SCOTUS) has yet to decide on mifepristone access in the US; however, many predict that the decision will come by late spring, June or July 2024 at the latest....

Over-the-Counter Birth Control Will Be $20 Per Monthly Supply

by Veronica Salib

On March 4, 2024, Perrigo Company, the manufacturer of Opill, announced that a monthly supply of the hormonal birth control pill costs $19.99 and is now available for pre-order. The product — and...

Comparing Female Fertility Drugs: Use Cases, Effectiveness, Risks

by Veronica Salib

Infertility, or the inability to conceive, is characterized by one year of unprotected sex without a subsequent pregnancy. Although infertility can result from male or female partners, most available fertility drugs work on addressing...

A Pulse Check on Advancements in the Life Sciences, Pharma Industry

by Alivia Kaylor

In the life sciences and pharmaceutical industry, 2023 has seen remarkable advancements and breakthroughs that hold great promise for the future of healthcare. In a recent podcast episode of the Healthcare Strategies, Senior Editor Alivia...

Sage Therapeutics Announces Wholesale Cost of Zuranolone, $15,900

by Veronica Salib

On November 7, 2023, Sage Therapeutics, the manufacturer of ZURZUVAE (zuranolone), announced that the wholesale acquisition cost of the postpartum depression drug would be $15,900 for a 14-day...

Taking Anti-Inflammatory Medication with Plan B Improves Effectiveness

by Veronica Salib

A new study published in the Lancet provides a new route for improving the effectiveness of oral emergency contraceptives. According to the study, taking an anti-inflammatory pill alongside Plan B...

Understanding HIV Drug Resistance, Minimizing Disease Transmission

by Veronica Salib

Despite having multiple tools and resources to minimize the transmission of human immunodeficiency virus (HIV), the growing rate of drug resistance has forced scientists and medical professionals to explore viral mutations more...

FDA Approves Zuranolone for Postpartum Depression

by Veronica Salib

Last week, the United States Food and Drug Administration approved the first oral treatment for postpartum depression (PPD). Zuranolone was approved on August 4, 2023, just days after a study in the...

Lupin Pharmaceuticals Recalls Two Lots of Birth Control

by Veronica Salib

On July 28, 2023, Lupin Pharmaceuticals, a manufacturer based out of Baltimore, MD, voluntarily recalled two lots of Tydemy. The drug is an estrogen and progestin oral contraceptive, also known as a...

Zuranolone Effectively and Safely Treats Postpartum Depression

by Veronica Salib

A study published in the American Journal of Psychiatry on July 26, 2023, proved that zuranolone could effectively and safely treat postpartum depression. The study supports the priority review granted...

FDA Approves Over-the-Counter, Nonprescription Birth Control

by Veronica Salib

After months of deliberation, the United States Food and Drug Administration (FDA) approved the first hormonal oral contraceptive for non-prescription over-the-counter (OTC) sale. This historical...

Research Explores the Harmful Health Effects of Recycled Plastics

by Veronica Salib

Despite the narrative that recycled plastic is better for the environment and overall health, years of research have explored the harmful health effects linked to recycled plastics. In a report...

Adverse Birth Outcome Linked to Forever Chemical Exposure in Pregnancy

by Veronica Salib

On May 31, 2023, JAMA Network Open published an article detailing the impacts of perfluoroalkyl and polyfluoroalkyl substance (PFAS) exposure on birth outcomes. Researchers determined that exposure to...

Syphilis Rates Continue to Rise as Penicillin Availability Falls

by Veronica Salib

In April, the United States Food and Drug Administration (USFDA) announced a shortage of injectable penicillin, penicillin G benzathine, adding to the never-ending list of medications with supply chain...

FDA Advisory Panel Favors Over-the-Counter Birth Control Pill: Opill

by Veronica Salib

Echoing the voices of multiple major healthcare organizations and public health leaders, a joint FDA advisory panel favored making a birth control pill available over the counter (OTC). FDA leaders...

WHO Updates HPV Vaccine Guidelines: Shift Toward Single Dose Series

by Veronica Salib

Following the WHO Strategic Advisory Group of Experts on Immunization (SAGE) earlier this year, the organization released an article updating its human papillomavirus (HPV) vaccine guidelines after...

NIH Study Finds That Post-Exposure Doxycycline Reduces STI Rate

by Veronica Salib

An article published in the New England Journal of Medicine found that post-exposure doxycycline reduces sexually transmitted infection (STI) rates by two-thirds. The study found that men who have sex...

FDA Withdraws Approval of a Premature Birth Drug After 12 Years

by Veronica Salib

On April 6, 2023, the FDA Commissioner Robert M. Califf, MD, and Chief Scientist Namandjé Bumpus, PhD, announced the organization’s decision to withdraw the approval of Makena...

Recent Articles